Merck to seek emergency authorization for oral Covid treatment

Merck to seek emergency authorization for oral Covid treatment after ‘compelling results’ in trials

 

KEY POINTS

• A phase 3 trial of Merck and Ridgeback Biotherapeutics’ oral antiviral treatment molnupiravir showed it reduced the risk of hospitalization or death by around 50% in Covid-19 patients.
• Merck plans to seek Emergency Use Authorization in the U.S. and submit marketing applications to other global drug regulators.
• If authorized by regulatory bodies, molnupiravir could be the first oral antiviral medicine for Covid-19.

https://www.cnbc.com/2021/10/01/merck-to-seek-emergency-authorization-for-oral-covid-19-treatment.html

https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/

https://www.wenxuecity.com/news/2021/10/01/10946654.html

所有跟帖： 

• 疫苗能力有窮時，疫苗安全尚未全，藥物開發及時雨，老藥新用是必然 -楓林曉- ♂ (110 bytes) () 10/01/2021 postreply 05:11:03

• 對照組有8例死亡而用藥組沒死亡，效果真的不錯，默克開盤前股票暴漲8% -走順路- ♂ (0 bytes) () 10/01/2021 postreply 05:51:46

• 50%有效,不知FDA會不會批準？ -5181- ♂ (0 bytes) () 10/01/2021 postreply 05:54:58

• 要是三期臨床最終表現還是這樣，而且沒有駭人聽聞的副作用，肯定會批複。成為戰勝新冠的利器 -fuz- ♂ (0 bytes) () 10/01/2021 postreply 06:59:08

• 默克原文，使用Molnupiravir三期臨試的進展報告：可以減少一半輕、中症患者轉重或死亡。這是迄今為止，效果最好的口服治療藥 -fuz- ♂ (5514 bytes) () 10/01/2021 postreply 06:34:12

• 優點：1.效果似乎不受基礎病的影響；2. 與變異株無關；3. 有巨大的生產潛力，可以快速推廣應用 -fuz- ♂ (0 bytes) () 10/01/2021 postreply 06:56:19

• 大廠宣傳就是牛，到現在，媒體上一片正麵期待。安全問題可能很大，沒人敢說？ -楓林曉- ♂ (0 bytes) () 10/01/2021 postreply 07:01:17

• 有， -fuz- ♂ (4505 bytes) () 10/01/2021 postreply 07:37:13

• 好。總算有一處存留。你看到meidia宣傳裏有寫這些問題的嗎？ -楓林曉- ♂ (0 bytes) () 10/01/2021 postreply 08:19:54